Breast cancer can spread to the layers of tissue that line and protect the brain, called leptomeningeal disease (LD). Click to learn about current research studying how to treat and manage LD.
Treatment resistance is when cancer does not respond to a drug. Read about research studying why resistance happens and how to overcome resistance.
Lobular breast cancer is difficult to detect with imaging scans. Researchers are studying a new method to improve detecting lobular breast cancer when it spreads. Read more here.
Researchers are working to understand the complex reasons for differences in MBC outcomes. Understanding these differences could allow for more personalized treatment. Learn more here.
Over time, people may develop resistance to CDK4/6 inhibitors, which means the drugs stop working. Learn about new strategies being studied in clinical trials to overcome resistance.
Tolerability is the ability to take a drug without experiencing side effects that cause you to stop taking it or reduce its dose. Click to read how clinical trials are studying ways to make MBC treatment easier to tolerate.
AI (Artificial Intelligence) is being studied for its ability to improve clinical trials, predict response to treatment, and more. Read below to learn more about how AI may help people with MBC.
Lobular MBC is harder to detect and spreads to different places in the body compared to ductal MBC. Click to learn more about recent research and clinical trials for lobular MBC.
The microbiome is the community of bacteria, viruses, and fungi in your body. Learn about the microbiome and how it may affect MBC and treatment.
Click to learn about elacestrant (Orserdu) as well as the Guardant360 blood test that identifies people likely to benefit from the drug.
